A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS IN SUBJECTS RECEIVING STANDARD OF CARE THERAPY
- Registry ID
- MEA115921
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2014-10-23
- Last update
- 2013-12-13
Conditions
- EOSINOPHILIC GRANULOMATOSIS
Related clinical trials
- A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NS-229 IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
- 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB COMPARED WITH MEPOLIZUMAB IN ADULTS WITH RELAPSING OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) RECEIVING STANDARD OF CARE (SOC) THERAPY
- A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED 52-WEEK STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB COMPARED TO MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN PATIENTS RECEIVING STANDARD OF CARE THERAPY
View on source registry